These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34599923)

  • 1. Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018.
    Dunphy C; Zhang K; Guy GP; Jones CM
    Prev Med; 2021 Dec; 153():106820. PubMed ID: 34599923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.
    Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT
    Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults.
    Lin LA; Brummett CM; Waljee JF; Englesbe MJ; Gunaseelan V; Bohnert ASB
    J Gen Intern Med; 2020 Feb; 35(2):420-427. PubMed ID: 31820218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
    Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
    JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose.
    Follman S; Arora VM; Lyttle C; Moore PQ; Pho MT
    JAMA Netw Open; 2019 May; 2(5):e193209. PubMed ID: 31050777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
    Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
    Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone Prescribing Associated With Reduced Emergency Department Visits in the Military Health System.
    Costantino RC; Tilley LC; Gressler LE; Zarzabal LA; Vasquez CM; Peters S; Pakieser J; Highland KB; dosReis S
    Med Care; 2022 Dec; 60(12):901-909. PubMed ID: 36356291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal requirements and recommendations to prescribe naloxone.
    Haffajee RL; Cherney S; Smart R
    Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Naloxone Dispensing Among Individuals with High-Risk Opioid Prescriptions, USA, 2015-2019.
    Guy GP; Strahan AE; Haegerich T; Losby JL; Ragan K; Evans ME; Jones CM
    J Gen Intern Med; 2021 Oct; 36(10):3254-3256. PubMed ID: 33751410
    [No Abstract]   [Full Text] [Related]  

  • 14. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
    Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Take-Home Naloxone and the Need for a Publicly Funded Naloxone Supply.
    Kim HS; Aks SE
    J Addict Med; 2022 Jan-Feb 01; 16(1):1-3. PubMed ID: 33534277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
    Xu J; Mukherjee S
    Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-prescribing naloxone does not increase liability risk.
    Davis CS; Burris S; Beletsky L; Binswanger I
    Subst Abus; 2016; 37(4):498-500. PubMed ID: 27648764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State legal innovations to encourage naloxone dispensing.
    Davis C; Carr D
    J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.